• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Hugues Chabriat, Claudio L Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M Hermann, Katharina ALTHAUS, Sergi AMARO, Hee-Joon BAE, Zbigniew BAK, Leonardo BARBARINI, Pietro BASSI, Rodrigo BAZAN, Daniel BERECZKI, Tomasz BERKOWICZ, Joerg BERROUSCHOT, Dylan BLACQUIERE, Waldemar BROLASummaryBackgroundS44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical excitabi...
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial
Publication date: Available online 7 November 2019Source: The Lancet NeurologyAuthor(s): Michael Ahmadi, Inga Laumeier, Thomas Ihl, Maureen Steinicke, Caroline Ferse, Matthias Endres, Armin Grau, Sidsel Hastrup, Holger Poppert, Frederick Palm, Martin Schoene, Christian L Seifert, Farid I Kandil, Joachim E Weber, Paul von Weitzel-Mudersbach, Martin L J Wimmer, Ale Algra, Pierre Amarenco, Jacoba P Greving, Otto BusseSummaryBackgroundPatients with recent stroke or transient ischaemic attack are at high risk for a further vascular event, possibly leading to permanent disability or death. Although evidence-based treatments for ...
Source: The Lancet Neurology - November 8, 2019 Category: Neurology Source Type: research